...
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Life sciences licensing deals in the first quarter of 2018: updates and trends
【24h】

Life sciences licensing deals in the first quarter of 2018: updates and trends

机译:2018年第一季度生命科学许可交易:更新和趋势

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

During the first quarter of 2018, Cortellis Competitive Intelligence registered 879 new deals (excluding mergers and acquisitions) with a total disclosed deal value of approximately USD 35.2 billion as part of its ongoing coverage of licensing activity in the life sciences sector. This compares to 1,203 and USD 26.2 billion in the fourth quarter of 2017, and 1,158 and USD 31.8 billion in the first quarter of 2017. This meant a significant increase in the total disclosed deal value compared to these two previous periods (+34% and +10.7%, respectively), and included the USD 5.8 billion pact between Merck & Co. and Eisai which became the highest-value deal in the last 4-year opening quarters. However, during the first quarter of 2018 there was not a high number of signed agreements versus the fourth quarter of 2017 and the first quarter of 2017 (-27% and -24%, respectively), reaching a number similar to that in the first quarter of 2014 with a total of 931 agreements covered.
机译:2018年第一季度,Cortellis Competitive Intelligence注册了879笔新交易(不包括并购),披露的交易总价值约为352亿美元,作为其对生命科学领域许可活动持续报道的一部分。相比之下,2017年第四季度为1203美元和262亿美元,2017年第一季度为1158美元和318亿美元。这意味着,与前两个时期相比,披露的交易总价值显著增加(分别为+34%和+10.7%),其中包括默克公司(Merck&Co.)与Eisai签订的58亿美元协议,该协议成为过去4年开放季度中价值最高的交易。然而,与2017年第四季度和2017年第一季度相比,2018年第一季度签署的协议数量并不多(分别为-27%和-24%),达到了与2014年第一季度类似的数量,共涵盖931份协议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号